A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Hematology & Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Gastroenterology

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1186/s13045-024-01656-0

License

CC-BY-NC-ND

Other Formats

PDF